Carisoprodol

From Wikipedia, the free encyclopedia

Carisoprodol
Systematic (IUPAC) name
[2-methyl-2-(1-methylethylcarbamoyloxymethyl) pentyl]aminomethanoate
Identifiers
CAS number 78-44-4
ATC code M03BA02
PubChem 2576
DrugBank APRD00417
Chemical data
Formula C12H24N2O4 
Mol. mass 260.33 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 60%
Metabolism Hepatic (CYP2C19-mediated)
Half life 8 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

?

Legal status

-only(US) Scheduled in some U.S. states

Routes Oral

Carisoprodol is a skeletal muscle relaxant whose active metabolite is meprobamate. Although several case reports have shown that carisoprodol has abuse potential, it continues to be widely prescribed (not so in the United Kingdom where use of benzodiazepines is preferred). Carisoprodol is a colorless, crystalline powder, having a mild, characteristic odor and a bitter taste. It is slightly soluble in water and freely soluble in alcohol, chloroform and acetone. Its solubility is practically independent of pH. It is marketed in the United States under the brand name Soma, and in the United Kingdom and other countries under the brand name Carisoma.

Contents

[edit] Chemistry

It is a carbamic acid ester. Carisoprodol is a racemic mixture of two stereoisomers.

[edit] Effects

[edit] Side effects

These are somewhat rare when used at normal doses.

[edit] Pharmacokinetics

Carisoprodol has a rapid, 30 minute onset of action, with the aforementioned effects lasting for approximately 2–6 hours. It is metabolized in the liver via the cytochrome P450 oxidase isozyme CYP2C19, excreted by the kidneys and has an approximate 8 hour half-life.

[edit] References

APhA Drug Information Handbook

[edit] External links